New drug could soon thwart smallpox outbreaks
A smallpox pill could help stem an outbreak quickly.
An anti-smallpox pill could be on the way if a new compound that shows promise in animal tests proves safe and effective in humans. Such a pill could provide the best method for controlling an unforeseen smallpox outbreak, its developers claim.
The need for new ways to treat smallpox has only become an issue in recent years as the threat of a deliberate release of the virus intensifies. Smallpox - a highly contagious and often lethal viral disease - was officially eradicated by vaccination in 1979.
"We disguised cidofovir so the body thinks its a dietary fat," Hostetler explains. His team attached to cidofivirs active component a molecule called lecithin, a breakdown product of fat found in all foods. This Trojan horse approach tricks the body into absorbing the drug and carrying it to where it is needed.
Small doses of the new compound - called HDP-CDV - killed the virus in smallpox-infected cells. "The big surprise was that its antiviral activity went up 100-fold compared to cidofovir," says Hostetler.
A single, daily dose of the drug also cured mice of cowpox, Huggins found. Untreated mice died within days.
Whats more, cowpox was undetectable in the respiratory tracts of mice treated with HDP-CDV. Because smallpox is spread by infectious droplets that are coughed up, this finding suggests that HDP-CDV might help to stem an epidemic.
These early tests raise hope that HDP-CDV might be incorporated into an anti-smallpox pill that could be distributed widely without the need for public-health workers to administer it, says Hostetler.
"But there is tons of work left to do," he warns. Even though the new compound is based on an existing drug, it must undergo the same rigorous testing as any other. The team dont expect that process to begin for at least another year.
The possibility of an effective drug for smallpox is likely to fuel the debate among smallpox experts about the best way to control a future outbreak. Many prominent scientists argue that antiviral drugs such as cidofivir shouldnt play a prominent role.
Antivirals may save lives and perhaps reduce transmission, but they do not confer immunity to the disease, as vaccines do, the argument goes.
Donald Henderson, head of George W. Bushs newly created Office of Public Health Preparedness, is a prominent sceptic. The use of cidofovir "would be limited to administration at or shortly after infection had occurred to prevent the virus from multiplying and eventually causing disease", he says.
Antiviral drugs would best be used to treat people who cant be vaccinated, says Henderson. Those with weak immune systems can suffer adverse, even fatal, reactions to smallpox vaccine.
Joseph Esposito, a poxvirus specialist at the US Centers for Disease Control and Prevention in Atlanta, Georgia, agrees: "A new drug would be very important." But in terms of a national strategy, "the first line of defence is a proven one, and thats vaccination," he says.
But while questions loom about the number of smallpox vaccine doses available to limit an outbreak, and about the possibility of a smallpox virus being engineered that can outwit existing vaccines, antivirals deserve a fair trail, says Hostetler.
TOM CLARKE | © Nature News Service
Oxygen can wake up dormant bacteria for antibiotic attacks
08.12.2016 | Penn State
NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
08.12.2016 | Life Sciences
08.12.2016 | Physics and Astronomy
08.12.2016 | Materials Sciences